Publish time: 2023-02-17 00:00:00
13A-1110114
Patent Pending
Cancer is one of the major fatal diseases known in the world. However, the traditional therapy of cancer through different approaches have their limitations. Lately, the natural killer (NK) cells have emerged as a potent tool for cancer therapy. Previously, we has generated a healthy longevity/anti-cancer mouse model, Eklf (K74R), and found that upon transplantation of bone marrow mononuclear cells (BMMNC) containing the hematopoietic stem/ progenitor cells (HSPC) from the Eklf (K74R) mice, the wild-type recipient mice would gain anti-cancer ability from the Eklf (K74R) mice. Transplantation of mouse NK cells into tumor-bearing NSG mice showed that the primary NK cells from the Eklf (K74R) mice have stronger ability to inhibit cancer cell growth than wild-type NK cells and also have higher cancer cell-killing ability in vitro. Furthermore, transplantation of the bone marrow mononuclear cells (BMMNC) was carried out and successed in the transfer of the long-life character to wild type (WT) mice. These data suggest that the mouse Eklf (K74R) hematopoietic/blood system or the orthologous human Eklf (K54R) blood system could be developed for uses in disease therapy as well as elongation of life span.
- Enhanced cancer cell-killing capability of nature killer cells carrying a specific amino acid substitution at the conserved sumoylation site, K74 in mouse EKLF and K54 in human EKLF;
- Transplantation of a specific genome-edited hematopoietic blood system could be a novel way for extending life-span/health-span of the animals including human.
General applications in cancer therapy and extension of life span/health span with use of a novel genetically engineered hematopoietic/blood system.
Che-Kun James Shen, Chun-Hao Hung, Shih-Ling Huang, Keh-Yang Wang, Jing-Ping Wang and Zheng-Sheng Lai
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Request for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office

Use of A Novel Genetically Engineered Hematopoietic/ Blood System for Disease Therapy and Extension of Life Span